(Circulation. 1996;94:2551-2559.)
© 1996 American Heart Association, Inc.
Articles |
the Departments of Anesthesiology and Pharmacology (D.M.D., M.J.P.R., J.R.M.) and the Departments of Medicine and Pharmacology (L.B.), University of Florida, Gainesville.
Correspondence to Luiz Belardinelli, MD, Department of Medicine, University of Florida, 1600 SW Archer Rd, PO Box J-100277, JHMHC, Gainesville, FL 32610.
Background There has been increasing interest in the development of agents that utilize endogenous adenosine to exert their actions. We tested the hypothesis that substances that either potentiate the activity (allosteric enhancers) or increase the interstitial concentration (inhibitors of metabolism) of endogenous adenosine may cause event (tachycardia)-specific depression of AV nodal conduction.
Methods and Results The frequency-dependent effects of iodotubercidin (ITU, an inhibitor of adenosine kinase), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA, an inhibitor of adenosine deaminase), draflazine (a nucleoside transport blocker), and PD81,723 (an allosteric enhancer of the A1 adenosine receptor binding) on the stimulus-toHis bundle (SH) interval, a measure of AV nodal conduction, were determined in guinea pig hearts and compared with those of adenosine and diltiazem. All drugs depressed AV nodal conduction in a frequency-dependent manner. The ratios of SH interval prolongations at fast to slow pacing rates for draflazine, ITU+EHNA, PD81,723, adenosine, and diltiazem were 17.5±3.4, 11.1±5.0, 3.5±0.9, 10.1±2.8, and 8.3±3.5, respectively. Coincident with the prolongation of the SH interval at rapid pacing rates, draflazine and ITU+EHNA increased the epicardial fluid adenosine concentrations by 2.2- and 2.6-fold, respectively. In contrast, epicardial transudate levels of adenosine do not change in the presence of PD81,723. The AV nodal effects of draflazine, ITU, EHNA, and PD81,723 were reversed by the A1 adenosine receptor antagonist 8-cyclopentyltheophylline and adenosine deaminase, implicating endogenous adenosine acting at the A1 adenosine receptor.
Conclusions Adenosine-regulating agents that act in an event- and site-specific manner represent a novel drug design strategy that may potentially be valuable for the long-term treatment of supraventricular arrhythmias and control of ventricular rate during atrial fibrillation or flutter.
Key Words: arrhythmia antiarrhythmia agents electrophysiology pharmacology tachycardia
This article has been cited by other articles:
![]() |
C. P. Cannon, S. Husted, R. A. Harrington, B. M. Scirica, H. Emanuelsson, G. Peters, R. F. Storey, and for the DISPERSE-2 Investigators Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Primary Results of the DISPERSE-2 Trial J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1844 - 1851. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Belardinelli, J. C. Shryock, S. Snowdy, Y. Zhang, A. Monopoli, G. Lozza, E. Ongini, R. A. Olsson, and D. M. Dennis The A2A Adenosine Receptor Mediates Coronary Vasodilation J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1066 - 1073. [Abstract] [Full Text] |
||||
![]() |
S. A Manthei, C. M Reiling, and D. G.L Van Wylen Dual cardiac microdialysis to assess drug-induced changes in interstitial purine metabolites: adenosine deaminase inhibition versus adenosine kinase inhibition Cardiovasc Res, January 1, 1998; 37(1): 171 - 178. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |